MedTrace Logo

A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression

NCT00289484 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2006-09-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether augmentation of antidepressant medication with Omega-3 polyunsaturated fatty acids increases the speed and degree of improvement for patients with major depression

Conditions

Interventions

DRUG

Omega-3 Polyunsaturated Fatty Acids

Sponsors & Collaborators

  • Your Health Inc.

    collaborator OTHER

  • Sphere Healthcare

    collaborator INDUSTRY

  • Ocean Nutrition

    collaborator INDUSTRY

  • The University of New South Wales

    lead OTHER

Principal Investigators

  • Gordon B Parker, Dsc MD PhD · Professor, School of Psychiatry UNSW and Exectutive Director, Black Dog Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00289484 on ClinicalTrials.gov